Medica Sur SAB de CV

Medica Sur has a market capitalization of MXN 6.58 billion, with a market price of MXN 61.00 per share, and no dilution risk based on current share counts, as shares outstanding remain unchanged between basic and diluted measures. However, liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents. The company’s profitability and returns are not directly quantifiable due to the absence of key financial metrics such as ROIC, EBITDA margins, or net profit margins in the valuation snapshot. Without these, a direct comparison to industry_config preferred metrics and cohort medians is not possible. Medica Sur operates through multiple subsidiaries and provides services across a broad range of medical specializations, including cardiology, oncology, and radiology. It also offers medical tourism and drug distribution services. No specific revenue concentration by segment or geography is disclosed, but the company’s operations are primarily based in Mexico. Outlook data is not available for the current or next fiscal year, and no revenue history is provided in the input data. Analysts have issued a single "Buy" recommendation with a mean price target of MXN 92.00, indicating a potential upside of 50.82% from the current market price. The company’s risk profile is limited to the absence of liquidity risk assessment and no immediate dilution risk. No recent filings or transcripts are provided in the input data to inform recent events or strategic shifts. No specific R&D or capex outlook is disclosed in the input data, and no segment-specific outlooks are available for further analysis.